Journal
CHINESE CHEMICAL LETTERS
Volume 33, Issue 10, Pages 4600-4604Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cclet.2022.04.033
Keywords
Breast cancer; Daunorubicin; Cytarabine; Co-delivery; Liposomes
Categories
Funding
- National Natural Science Foundation of China [81872823, 82073782]
- China Pharmaceutical University [CPU2018PZQ13]
- Shanghai Science and Technology Committee [19430741500]
- Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine [zdsys-202103]
Ask authors/readers for more resources
A targeted co-delivery system of daunorubicin and cytarabine was developed, showing good stability and endocytosis capability, which could be utilized for the treatment of breast cancer.
Breast cancer is the most prevalent cancer in women, and it was hard to prevent or diagnose at an early stage. Thus, it is imperative to develop advanced therapeutics for effective treatment. Herein, a targeted daunorubicin (DNR) and cytarabine (ara-C) co-delivery system was developed by modifying the ara-C loaded liposomes (LIP-ara-C) with the hyaluronic acid-DNR (HA-DNR) prodrugs. The co-assembled hybrid nanoparticles (HA-DNR/LIP-ara-C HNPs) exhibited good serum and storage stability with an average diameter of approximately 100 nm. By specifically binding to the CD44 receptors that overexpressed on cancer cells, these HNPs could be uptake via endocytosis and accumulate intracellularly, in which an optimized DNR and ara-C combination at a molar ratio of 1:5 could generate enhanced synergistic effects with reduced dose-related toxicity on cancer cells. (C) 2022 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available